Estrella Immunopharma risks Nasdaq delisting after market value falls below $35 million threshold

PUBT · 1d ago
Estrella Immunopharma risks Nasdaq delisting after market value falls below $35 million threshold
  • Estrella Immunopharma received a Nasdaq notice for failing the $35 million market value of listed securities rule.
  • MVLS stayed below $35 million for 30 straight business days from July 21 through Aug. 31, 2026.
  • Nasdaq also flagged noncompliance with alternative standards for stockholders’ equity or net income.
  • Shares keep trading on Nasdaq Capital Market; deadline to regain compliance is March 1, 2027.
  • Failure to cure by then could trigger a delisting notice, with an option to appeal to a Nasdaq hearings panel.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-098123), on September 08, 2026, and is solely responsible for the information contained therein.